Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

T. Ochi S. Makita Anna Hiratsuka Risa Nishiyama K. Ito Akiko Miyagi Maeshima Wataru Takeda Noriko Iwaki S. Fukuhara W. Munakata Koji Izutsu

Aug 2026 · International Journal of Clinical Oncology · 0 citations · 25 references

Medicine

TL;DR

The efficacy of CAR T-cell therapy in patients with R/R HGBCL remains suboptimal, and high-grade morphology may help identify patients at particularly high risk of poor outcomes following CAR T-cell therapy.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Open access Sep 2026

Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.

The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.

P. Caimi, Romano Danesi, G. Iacoboni et al. · Blood reviews · 0 citations

Open access Aug 2026

Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.

This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.

Xi Yang, Henry Dumke, Swetha Kambhampati Thiruvengadam et al. · Blood Advances · 0 citations

Aug 2026

Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models.

Outcomes after CAR-T failure in LBCL remain poor despite the availability of multiple salvage treatment strategies, and time to relapse after CAR-T therapy was the strongest prognostic factor.

Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai et al. · Transplantation and Cellular... · 0 citations

Open access Sep 2026

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease-negative remission, with durable EFS in pediatric B-ALL, and support further evaluation in prospective trials.

Xinyu Wan, Yan-Jing Tang, Jiao-Yang Cai et al. · JAMA Oncology · 1 citation

Case report Open access Aug 2026

Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report

Background Therapy-related myeloid neoplasms (t-MNs) have emerged as a serious late complication of CD19-directed chimeric antigen receptor (CAR) T-cell therapy. While large-scale studies have characterized the epidemiology of t-MNs, the mechanisms underlying their development remain incompletely understood, and cases...

Manqi Su, Chentong Huang, Zhan-Na Zhang et al. · Frontiers in Medicine · 0 citations

Clinical trial Sep 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study was executed in five hospitals in the Netherlands and Belgium to evaluate the safety and determine the recommended phase 2 dose of GLPG5101.

M. Kersten, M. Kuipers, P. Mutsaers et al. · The Lancet Haematology · 0 citations